Amicus Therapeutics (FOLD) Financials

Amicus Therapeutics Inc (FOLD) is a biopharmaceutical company that focuses on the development of treatments for rare and orphan diseases. The company's financials reflect its commitment to advancing innovative therapies. When looking at the income statement, it is evident that Amicus Therapeutics has been steadily increasing its revenues over the years. In the most recent fiscal year, the company reported a total revenue of $263 million. This growth can be attributed to the strong sales performance of its flagship product, Galafold, which treats Fabry disease.

The company's gross profit for the same period was $189 million. This indicates that Amicus Therapeutics has been able to generate significant revenue after deducting the cost of goods sold. Additionally, the company has been able to manage its operating expenses effectively, resulting in a positive EBIT (earnings before interest and taxes) of $34 million. This shows that Amicus Therapeutics has been able to generate profits from its core operations.

EBITDA (earnings before interest, taxes, depreciation, and amortization) provides a clearer picture of the company's profitability as it eliminates non-operating expenses. In the most recent fiscal year, Amicus Therapeutics reported an EBITDA of $53 million. This suggests that the company has been able to generate healthy cash flows from its primary business activities.

One important aspect of Amicus Therapeutics' financials is its net income from stockholders. This figure represents the profit available to common shareholders after deducting all expenses. In the most recent fiscal year, the company's net income from stockholders was $19 million. This indicates that Amicus Therapeutics has been able to generate profits for its shareholders.

Amicus Therapeutics' balance sheet reflects its financial position at a specific point in time. The company has a strong cash position, with cash equivalents amounting to $274 million. This indicates that the company has sufficient liquidity to fund its operations and invest in research and development.

When considering the company's debt obligations, Amicus Therapeutics has a net debt of $226 million. Net debt is calculated by deducting cash and cash equivalents from total debt. In this case, Amicus Therapeutics has more debt than cash. However, this is not necessarily a cause for concern as the company's strong revenue growth and profitability indicate its ability to service its debt obligations.

Stockholders' equity represents the residual interest in the assets of the company after deducting liabilities. For Amicus Therapeutics, stockholders' equity stands at $461 million. This indicates that the company has a solid financial foundation.

The company's total assets, which include both tangible and intangible assets, amount to $1.08 billion. This indicates that Amicus Therapeutics has a significant asset base to support its operations and growth.

Amicus Therapeutics' total debt, which includes both short-term and long-term obligations, stands at $500 million. This demonstrates the company's reliance on debt financing to support its operations and research initiatives.

Total liabilities, including both current and long-term obligations, amount to $778 million. This represents the company's financial obligations to external parties.

Cash flow refers to the movement of money in and out of a company. Amicus Therapeutics has a positive cash flow from its operating activities, indicating that the company's core business generates sufficient cash to support its operations. The company's operating cash flow for the most recent fiscal year was $43 million.

The company's financing cash flow reflects the inflow and outflow of funds related to financing activities such as issuing stock or repaying debt. In the most recent fiscal year, Amicus Therapeutics reported a financing cash flow of $182 million, indicating that the company has been actively seeking funding to support its growth initiatives.

Free cash flow is a measure of a company's ability to generate cash after accounting for capital expenditures required to maintain or expand its asset base. In the most recent fiscal year, Amicus Therapeutics reported a free cash flow of $7 million. This suggests that the company has been able to generate some cash for potential investment or debt repayment.

Investing cash flow reflects the cash inflows and outflows related to investments in assets or divestments of assets. For Amicus Therapeutics, the investing cash flow for the most recent fiscal year was -$250 million. This indicates that the company has made significant investments in research and development, acquisitions, or capital expenditures.

Overall, Amicus Therapeutics Inc (FOLD) has demonstrated strong financial performance, with increasing revenues, profitability, and a solid balance sheet. The company's ability to generate positive cash flows and effectively manage its debt obligations is a testament to its financial stability and growth potential.